Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
17.04
-0.06 (-0.35%)
May 8, 2025, 4:00 PM EDT - Market closed
Pharvaris Employees
Pharvaris had 108 employees as of December 31, 2024. The number of employees increased by 26 or 31.71% compared to the previous year.
Employees
108
Change (1Y)
26
Growth (1Y)
31.71%
Revenue / Employee
n/a
Profits / Employee
-$1,286,667
Market Cap
928.56M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PHVS News
- 4 weeks ago - Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission - GlobeNewsWire
- 2 months ago - Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress - GlobeNewsWire
- 2 months ago - Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025 - GlobeNewsWire
- 4 months ago - Pharvaris Outlines 2025 Strategic Priorities - GlobeNewsWire
- 6 months ago - Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates - GlobeNewsWire
- 6 months ago - Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 7 months ago - Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings - GlobeNewsWire